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The Nrf2-ARE system is a potential therapeutic target for cancers and neurodegenerative diseases. In this
issue, Hur et al. (2010) report the discovery of a novel modifiable Nrf2-ARE activator from the unbiased
high throughput screening of a small molecule library.The inhibitory effects of chemical agents
on the carcinogenic activities of others
were first reported in the early twentieth
century. Following this discovery, the
cancer chemopreventive potentials of
a variety of chemical compounds have
been identified (Holtzclaw et al., 2004).
Among them, those of naturally occurring
phytochemicals found in vegetables and
fruits, such as broccoli, grapes, ginger,
and turmeric, have captured public atten-
tion because they seem intuitively safer
than synthetic compounds. The identifi-
cation of phytochemicals responsible for
cancer chemopreventive effects has
been carried out (examples include sulfor-
aphane from broccoli, resveratrol from
grapes, zerumbone from ginger, and
curcumin from turmeric), and in vivo
targets of these compounds have been
extensively studied. One of the major
targets of these phytochemicals is the
gene induction of phase 2 detoxification
enzymes, such as glutathione-S trans-
ferases and NAD(P)H:quinone oxidore-
ductase (NQO1), which can detoxify
and/or excrete many harmful compounds
including carcinogens. The important
issue here is that these compounds indi-
rectly obviate carcinogens by inducing
cellular defensemechanisms, so that their
effects can last even after the compounds
themselves have disappeared from cells.
A consensus sequence 50-TGACnnn
GC-30, which is essential for this induc-
tion, was found in the phase 2 detoxifica-
tion genes. It was named antioxidant
response element (ARE) because the
most potent inducers in the early era
were phenolic food antioxidants such
as tert-butylhydroquinone (tBHQ). Later,
transcription factor Nrf2 was identified
as the only trans-acting factor that canbind to ARE and transactivate the phase
2 genes (Kobayashi and Yamamoto,
2006). Under basal conditions, Nrf2 is
rapidly degraded by proteasome, and
little induction of target genes is
observed. This degradation is controlled
by Keap1, an Nrf2-specific adaptor pro-
tein for the Cul3 ubiquitin ligase complex.
Nrf2-ARE activating compounds block
Keap1-dependent Nrf2 ubiquitination,
thus leading to the stabilization and
nuclear accumulation of Nrf2 and the
subsequent induction of Nrf2 target
genes.
The critical roles of Nrf2 in cancer che-
moprevention have been demonstrated
using Nrf2-knockout mice (Kwak and
Kensler, 2010). Mice pretreated with
Nrf2-ARE activating compounds, such
as oltipraz, show Nrf2-dependent reduc-
tion of tumor formation. In addition to
cancer chemopreventive effects, the neu-
roprotective potentials of Nrf2-ARE acti-
vators have recently become a hot topic
since antioxidant proteins, such as heme
oxygenase 1 and superoxide dismutase 1,
have been identified as Nrf2 targets
(Vargas and Johnson, 2009). Oxidative
stress has been implicated in the patho-
genesis of several neurodegenerative
diseases, such as Alzheimer’s and Parkin-
son’s diseases. Nrf2 activation protects
both neurons and astrocytes from oxida-
tive damage in many different acute para-
digms, and it is a promising therapeutic
target in chronic neurodegeneration. It
is therefore considered worthwhile to
develop highly active and low toxic Nrf2-
ARE activating compounds.
In this issue, Hur et al. (2010) report on
the identification of Nrf2-ARE activating
compounds from an unbiased screen of
a chemical library. There are two impor-Chemistry & Biology 17, May 28, 2010tant points in this paper. First, this is the
first report of a large-scale systematic
screen for Nrf2-ARE activators. Screening
was carried out by means of a human
neuroblastoma cell line and an ARE-
dependent reporter gene. One hundred
and seventeen small molecule activators
were isolated from 1.2 million com-
pounds. Among them, seven available
lead compounds were further character-
ized, and a chloropyrimidinone, named
here AI-1 (ARE-inducing compound 1),
was selected for further characterization
because of its decreased toxicity in
comparison to others (Figure 1). AI-1
showed similar inducing activities as the
tBHQ of the ARE-reporter and endoge-
nous NQO1 genes. Resistance to
hydrogen peroxide in neuroblastoma cells
was elevated by AI-1 treatment. Biotin-
modified AI-1 was demonstrated to bind
directly to Cys151 of Keap1 both in vivo
and in vitro, thus suggesting that Keap1
Cys151 is a target site for AI-1 in the
Nrf2-ARE system. Cys151, which is
located near the Cul3-binding site in
Keap1, is a well-known target for many
Nrf2-ARE activating compounds, such
as sulforaphane, tBHQ, and ebselen
(Kobayashi et al., 2009). AI-1-binding
at Cys151 weakened the interaction
between Keap1 and Cul3, thus inhibiting
the ubiquitination of Nrf2 and facilitating
the stabilization and nuclear accumula-
tion of Nrf2. Second, the extensivemolec-
ular dissection of AI-1 was carried out,
which clarified the critical and tolerable
chemical structures in AI-1 (Figure 1).
The finding of tolerable structures is valu-
able, since the compound thus became
modifiable tomore useful or effective acti-
vators. For example, a biotin group was
able to be added to AI-1 without obviatingª2010 Elsevier Ltd All rights reserved 419
Figure 1. Cancer Chemoprevention and Neuroprotection by Nrf2-ARE Activating
Compounds
Most of the known potent Nrf2-ARE activating compounds are unmodifiable, while compounds isolated
from the unbiased screens of chemical libraries such as AI-1 (Hur et al., 2010) can be modified to be
more useful or effective activators. The Nrf2-ARE system has multiple activating pathways that provide
us with an opportunity to design a variety of cancer chemopreventive and neuroprotective drugs.
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amide-biotin), which is a helpful tool for
analyzing protein interactions. It also rai-
ses the possibility of upgrading the lead
compound to less toxic and more target-
specific activators. Indeed, AI-2 which
has more potent Nrf2-ARE activating
activity than AI-1 was successfully gener-
ated by modifying the N1 side group.
This exciting work opens up a new fron-
tier of drug discovery based on the Nrf2-
ARE system. Further screening may
make it possible to overcome the prob-
lems of off targets in the case of AI-1,420 Chemistry & Biology 17, May 28, 2010 ªwhich was shown in this paper to bind
HDACs and PP2A, as well as many other
proteins. To expand the scale of
screening, it will be helpful to determine
the 3D structure of the Keap1 protein con-
taining Cys151 and utilize this information
for in silico screening. It is noted that the
target sites of Nrf2-ARE activators are
not restricted to Cys151 of Keap1
(Figure 1) (Kobayashi et al., 2009). Some
activators, such as 15-deoxy-D12,14-pros-
taglandin J2, target different sites in
Keap1. Hydrogen peroxide and the anti-
rheumatic drug auranofin may target2010 Elsevier Ltd All rights reservedother proteins than Keap1 or Nrf2.
Recently, some proteins such as p62/
SQSTM1 and p21/Cip1/WAF1 have
been shown to directly target the Nrf2-in-
teracting site of Keap1 or the Keap1-inter-
acting site of Nrf2, respectively (Komatsu
et al., 2010; Chen et al., 2009). These
multiple sensing pathways of Nrf2-ARE
activation therefore provide us with
a chance to design a variety of Nrf2-ARE
activating drugs that are suitable for the
clinical conditions and severity of various
diseases. The current success of an unbi-
ased high-throughput screen for Nrf2-
ARE activators will encourage the future
development of new strategies in drug
discovery for cancer chemoprevention
and neuroprotection.REFERENCES
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